Archive
Every story, newest first.
Tuesday, November 10, 2026
Technology
Wix reported third quarter revenue of 570 million dollars, up 13 percent year on year, with bookings of 573 million dollars, as its Base44 AI app builder neared 250 million dollars of annual recurring revenue.
Technology
ASE Technology October revenue rose 47.1 percent year on year, ChipMOS reported third quarter net profit of NT$2.72 billion, and Vertiv signed a three year power semiconductor supply partnership with Infineon.
Technology
Utility PPL said its advanced stage data center pipeline in Pennsylvania grew 3.5 gigawatts in the quarter to 35.3 gigawatts, its eleventh consecutive quarterly increase, and raised its 2027 to 2030 capital plan to 25 billion dollars.
Technology
Infineon closed fiscal 2026 with record fourth quarter revenue of 4.706 billion euros and guided fiscal 2027 revenue to about 20 billion euros, with data center power supply revenue alone expected to reach close to 4 billion euros.
Technology
Akamai said an 11.6 billion dollar, seven year cloud commitment from Anthropic takes its multiyear cloud infrastructure commitments signed this year above 14 billion dollars, and that total revenue could surpass 7 billion dollars in 2028.
Life Sciences
Keenova raised its pro forma full-year net sales guidance to 2.00 billion to 2.025 billion dollars and its adjusted EBITDA guidance to 750 million to 770 million dollars after a stronger third quarter.
Life Sciences
Ionis cut full-year 2026 Tryngolza product sales guidance to about 50 million dollars from 100 million to 110 million dollars, while reaffirming total revenue guidance of 875 million to 900 million dollars.
Life Sciences
Delix Therapeutics closed an oversubscribed 100 million dollar Series C, co-led by Johnson and Johnson's venture arm, to take zalsupindole into a Phase IIb trial in recurrent major depressive disorder.
Life Sciences
CorMedix will acquire substantially all of Heron's assets for 145 million dollars in cash plus 14,583,333 CorMedix shares, with up to 55 million dollars more in earn-outs and royalties.
Life Sciences
Black Diamond reported an 86 percent central nervous system response rate for silevertinib in patients with untreated brain metastases, and FDA feedback supporting a pivotal trial with a potential accelerated approval path.